Zoladex (GnRH): Global Drug Analysis and Forecasts 2017-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Zoladex" drug pipelines has been added to ResearchAndMarkets.com's offering.

Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as "flare".

Persistent use of GnRH agonists over time causes downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration.

Key Topics Covered:

Product Profiles

Zoladex: Prostate cancer

List of Figures

Figure 1: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/tzn9rv/zoladex_gnrh?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Breast Cancer Drugs , Prostate Cancer Drugs , Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Breast Cancer Drugs , Prostate Cancer Drugs , Hematological Drugs